The White House announced nine additional most-favored-nation (MFN) pricing agreements with midsized biopharma companies, bringing participation to 26 manufacturers that cover 89% of the branded drug market. Under the voluntary deals, companies agree to align US prescription drug prices with the lowest prices paid by other developed nations. The new agreements include Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB, spanning medicines for conditions including hemophilia, Parkinson’s disease, glaucoma, liver disease, skin conditions, and cancers. The administration said Medicaid programs will have access to reduced prices, alongside commitments to invest in US manufacturing and donate certain active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve. Regulatory and market implications center on how fast these deals translate into formulary access and pricing behavior while manufacturers manage production investment obligations and supply chain resilience.